Trending down for 3 months because of ex CEO Martin Shrekli investigation and biotech bubble bursting. First target $13 followed by a dead cat bounce and ultimately down to 10.50 in March
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
